Tests clot-dissolving drug delivered into arteries for ischemic stroke from medium vessel blockage
Tests clot-dissolving drug given into an artery in adults with stroke.
Plain-language title generated from the registry record
Registry title: Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
Key facts
- Where
- Fuyang, Hefei, Lishui, Liuzhou, and Lu'an, ChinaSee the 6 sites
Where in China
- Fu Yang People's HospitalFuyang, ChinaTaking people
- Lin Quan People's HospitalFuyang, ChinaTaking people
- The Second Affiliated Hospital Of Anhui Medical UniversityHefei, ChinaTaking people
- Lishui Central HospitalLishui, ChinaTaking people
- Liuzhou Worker's HospitalLiuzhou, ChinaTaking people
- Shucheng People's HospitalLu'an, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Second Hospital of Anhui Medical University
- Trial code
- NCT07185022
- Record updated
- 16 April 2026
- Original description
Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.Read full original descriptionShow less
a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)
Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.
Inclusion: Age > 18 years; Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA); The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction); Intra-arterial thrombolysis was administered within the following time windows:; Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA; Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume <30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume; Signed informed consent obtained.
Exclusion: Secondary MeVO or severe stenosis caused by endovascular therapy; Pre-stroke mRS ≥ 2; Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders; Persistent and uncontrolled hypertension, defined as systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg; History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage; Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months; Patients with known allergy to thrombolytic agents or their excipients; Patients with known allergy to iodinated contrast agents or other established contraindications; Platelet count <100 × 10⁹/L, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) >3.0; Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) <30 mL/min or serum creatinine >220 μmol/L (2.5 mg/dL); Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory; Presence of arteriovenous malformations or brain tumors with mass effect; Pregnant or current breastfeeding; Presence of severe systemic comorbidities with a life expectancy of less than 3 months; Deemed unsuitable for participation by the investigator for any reason.